Pregabalin Capsule
NDC Package 73190-059-50
Package Information
Pregabalin capsules is a medication used to treat pain caused by nerve damage due to diabetes, shingles (herpes zoster) infection, or spinal cord injury. This formulation utilizes a capsule delivery system. Marketed by Avkare, this product is identified by NDC 73190-059 and is authorized under FDA application ANDA212988.
Identification & Billing
- RxCUI: 483438 - pregabalin 100 MG Oral Capsule
- RxCUI: 483440 - pregabalin 150 MG Oral Capsule
- RxCUI: 483442 - pregabalin 25 MG Oral Capsule
- RxCUI: 483444 - pregabalin 300 MG Oral Capsule
- RxCUI: 483446 - pregabalin 200 MG Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 73190 - Avkare
- 73190-059 - Pregabalin
- 73190-059-50 - 500 CAPSULE in 1 BOTTLE
- 73190-059 - Pregabalin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (73190-059). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 73190-059-50 identifies a specific commercial package of 500 capsule in 1 bottle of Pregabalin, a human prescription drug labeled by Avkare. This capsule is formulated for oral use and contains pregabalin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Avkare on December 09, 2025. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat pain caused by nerve damage due to diabetes, shingles (herpes zoster) infection, or spinal cord injury. This medication is also used to treat pain in people with fibromyalgia. It is also used with other medications to treat certain types of seizures (focal seizures).
How is this Avkare product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 73190005950. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.